Debkishore Mitra Ph.D.
Net Worth

Last updated:

What is Debkishore Mitra Ph.D. net worth?

The estimated net worth of Dr. Debkishore Mitra Ph.D. is at least $934,374 as of 1 Sep 2022. He has earned $324 from insider trading and has received compensation worth at least $934,050 in Lucira Health, Inc..

What is the salary of Debkishore Mitra Ph.D.?

Dr. Debkishore Mitra Ph.D. salary is $311,350 per year as Chief Technology Officer & Director in Lucira Health, Inc..

How old is Debkishore Mitra Ph.D.?

Dr. Debkishore Mitra Ph.D. is 38 years old, born in 1987.

What stocks does Debkishore Mitra Ph.D. currently own?

As insider, Dr. Debkishore Mitra Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Lucira Health, Inc. (LHDX) Chief Technology Officer & Director 382,208 $0 $0

What does Lucira Health, Inc. do?

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Debkishore Mitra Ph.D. insider trading

Lucira Health, Inc.

Dr. Debkishore Mitra Ph.D. has made only one insider trade in 2022, according to the Form 4 filled with the SEC. He sold 191 units of LHDX stock worth $324 on 1 Sep 2022.

As of 1 Sep 2022 he still owns at least 382,208 units of LHDX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 191 $1.69 $324

Lucira Health key executives

Lucira Health, Inc. executives and other stock owners filed with the SEC: